CTGF
Assets acting on this target.
- Class
- Anti-CTGF antibody
Assets acting on this target.
3 of 3 assets (3 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Pamrevlumab | Kyntra Bio | CTGF | Idiopathic Pulmonary Fibrosis | Ph 3 | The IPF programme is dead. ZEPHYRUS-1 (NCT03955146) is recorded TERMINATED because the 'Study did not meet its primary endpoint', with the JAMA report opened this session confirming the FVC primary endpoint was missed; the report opened this session states that 'Based on this failure, FibroGen called it quits on a second Phase III trial for IPF, ZEPHYRUS-2', matching NCT04419558's TERMINATED status. A CT.gov intervention query run this session returns twenty pamrevlumab studies, five of them carrying an IPF condition, and the latest-starting of those is ZEPHYRUS-2 itself (2020-09-30): nothing has been registered in IPF since the terminated Phase 3 programme. | source ↗ |
| Pamrevlumab | Kyntra Bio | CTGF | Type 2 Diabetes | Ph 2 | StrategicFG-3019 (pamrevlumab) was initially developed to target diabetic nephropathy, but per a fibrosis-field review this program failed clinically in early development, with the compound's later development redirected entirely to pancreatic cancer, IPF, and DMD (all of which also subsequently failed at Phase III). | source ↗ |
| Pamrevlumab | Kyntra Bio | CTGF | Chronic Hepatitis B | Ph 2 | NCT01217632 (Phase 2, randomized, placebo-controlled, fetched this session) is TERMINATED. Consistent with the drug's persisted T2D-market profile, FibroGen/Kyntra Bio's CTGF program was redirected away entirely to pancreatic cancer, IPF and DMD (which also later failed at Phase III); no continuing chronic-HBV fibrosis work was found. | source ↗ |